Completed

High-dose Antioxidants for Central Serous Chorioretinopathy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

antioxidants tablets

Drug
Who is being recruted

Eye Diseases

+ Retinal Diseases

+ Central Serous Chorioretinopathy

From 30 to 50 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 2
Interventional
Study Start: December 2004
See protocol details

Summary

Principal SponsorPrince of Songkla University
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 1, 2004

Actual date on which the first participant was enrolled.

Central serous chorioretinopathy (CSC) is the serous neurosensory detachment that usually involves the macular area. It is common in patients between 30-50 years old and effects male more often than female with the ratio of 5-10. The common risk factors are psychologic stress, type A personality, systemic steroid use, hypertension and pregnancy. The treatment is usually observation especially in the first three-months. The laser or photodynamic therapy should be considered when the condition does not improve after that time. Nevertheless, the pathogenesis of CSC is still not well understood but the study from indocyanine green angiography showed the choroidal vascular hyperpermeability and abnormal leakage. The causes of this abnormality are supposed to be from nitric oxide, prostaglandins or even free oxidative radicals. From this hypothesis, the oxidative process might be involved in the pathogenesis of the disease especially in the early stage. This study is to determine the effect of antioxidants drugs in the acute stage of CSC and to determine whether they can improve the outcomes of the disease.

Official TitleHigh-dose Antioxidants for Central Serous Chorioretinopathy
NCT00963131
Principal SponsorPrince of Songkla University
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

60 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 30 to 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesRetinal DiseasesCentral Serous Chorioretinopathy

Criteria

5 inclusion criteria required to participate
patients with acute central serous chorioretinopathy within 6 weeks of onset

age between 30-50 years

new or recurrent attack (the symptom-free period should longer than 6 months)

fluorescein angiography (FA) confirmed the diagnosis with the inkblot or smoke-stack leakage and the optical coherence tomography (OCT) showed definite subretinal fluid

Show More Criteria

3 exclusion criteria prevent from participating
chronic central serous chorioretinopathy(longer than 6 weeks)

complicated central serous chorioretinopathy such as secondary choroidal neovascularization (CNV) that detected from FA

pregnancy, steroid user and patients that contraindicated for high dose antioxidants therapy such as heavy smokers, lung cancer, thyrotoxicosis, renal stone and anemia (hematocrit less than 30%).

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease

Group II

Placebo
the control arm received placebo tablets for 3 months or until the resolution of the disease

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Department of Ophthalmology, Faculty of medicine, Prince of Songkla university

Hat Yai, ThailandOpen Department of Ophthalmology, Faculty of medicine, Prince of Songkla university in Google Maps
CompletedOne Study Center
High-dose Antioxidants for Central Serous Chorioretinopathy | PatLynk